Theseus Pharmaceuticals I... (THRX)
Theseus Pharmaceuticals Statistics
Share Statistics
Theseus Pharmaceuticals has 44.65M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 44.65M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 14.26M |
| Failed to Deliver (FTD) Shares | 1.5M |
| FTD / Avg. Volume | 177.03% |
Short Selling Information
The latest short interest is 401.68K, so 0.9% of the outstanding shares have been sold short.
| Short Interest | 401.68K |
| Short % of Shares Out | 0.9% |
| Short % of Float | 1.9% |
| Short Ratio (days to cover) | 1.08 |
Valuation Ratios
The PE ratio is -4.07 and the forward PE ratio is null. Theseus Pharmaceuticals's PEG ratio is 0.07.
| PE Ratio | -4.07 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.92 |
| P/FCF Ratio | -5.74 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Theseus Pharmaceuticals has an Enterprise Value (EV) of 101.05M.
| EV / Sales | 0 |
| EV / EBITDA | -1.87 |
| EV / EBIT | -3.07 |
| EV / FCF | -3.03 |
Financial Position
The company has a current ratio of 17.79, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.79 |
| Quick Ratio | 17.79 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.12 |
| Interest Coverage | 15.33 |
Financial Efficiency
Return on Equity is -22.68% and Return on Invested Capital is -23.78%.
| Return on Equity | -22.68% |
| Return on Assets | -21.16% |
| Return on Invested Capital | -23.78% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.24M |
| Employee Count | 38 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.53M |
| Effective Tax Rate | 6.97% |
Stock Price Statistics
The stock price has increased by 0.25% in the last 52 weeks. The beta is 3.98, so Theseus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 3.98 |
| 52-Week Price Change | 0.25% |
| 50-Day Moving Average | 3.99 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 59.85 |
| Average Volume (20 Days) | 849.6K |
Income Statement
| Revenue | n/a |
| Gross Profit | -438K |
| Operating Income | -54.09M |
| Net Income | -47.08M |
| EBITDA | -54.09M |
| EBIT | -54.14M |
| Earnings Per Share (EPS) | -1.22 |
Balance Sheet
The company has 94.61M in cash and 3.98M in debt, giving a net cash position of 90.63M.
| Cash & Cash Equivalents | 94.61M |
| Total Debt | 3.98M |
| Net Cash | 90.63M |
| Retained Earnings | -112.19M |
| Total Assets | 234.63M |
| Working Capital | 202.58M |
Cash Flow
In the last 12 months, operating cash flow was -32.95M and capital expenditures -455K, giving a free cash flow of -33.4M.
| Operating Cash Flow | -32.95M |
| Capital Expenditures | -455K |
| Free Cash Flow | -33.4M |
| FCF Per Share | -0.87 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
THRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.56% |
| FCF Yield | -17.42% |
Analyst Forecast
Currently there are no analyst rating for THRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 9.98 |
| Piotroski F-Score | 3 |